Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.
Latest From Dexter Yan
China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
Allorion Rides Unconventional Discovery Platforms To Major Funding
Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
Sino Biopharm Completes F-Star Acquisition After US CFIUS Review
Sino Biopharm's $161m all-cash acquisition of F-star has finally closed amid heightening US-China tensions and following completion the Chinese firm, through its UK subsidiary invoX, plans to expand its operations and presence at F-star’s UK headquarters.
China’s CDE Explains Major Issues Around Conditional Approval Scheme
China's conditional approval system, which is an accelerated pathway, is being increasingly used by pharma firms, but some thorny issues remain such as the impact on full approvals, the scheme’s relation to priority reviews and currently available therapies and deadlines for confirmatory studies. Staff from the country's Center for Drug Evaluation discussed various topics around the system in a recent article.